Crawford R J, Allman S, Kitchen S P, Richards H H
Medical Department, Rorer Health Care Ltd., Eastbourne, England.
Curr Med Res Opin. 1988;10(10):675-81. doi: 10.1185/03007998809111118.
Twenty-seven patients (mean age 72 years) with symptoms of congestive cardiac failure who had been controlled by treatment with 1 to 2 tablets per day of a combination preparation of frusemide (40 mg) and amiloride (5 mg) for at least 12 weeks were studied. The study was designed to assess the efficacy and tolerability of continuing treatment with the combination for a further 9 months, i.e. a total period of 12 months. Assessments of disease status and laboratory data were made every 3 months. Reasonable control of symptoms was achieved over the 12-month period although the majority of patients did not show a clinically important change. Some overall trends towards increasing oedema, dyspnoea and orthopnoea were observed as the study progressed, but these changes were not regarded as unusual considering the patients' age group. Significant increases in pulse rate and decreases in blood pressure were demonstrated, suggesting that diuresis was maintained. The combination preparation was well tolerated without any reports of side-effects.
对27例有充血性心力衰竭症状的患者（平均年龄72岁）进行了研究，这些患者每天服用1至2片速尿（40毫克）和阿米洛利（5毫克）的复方制剂进行治疗，至少持续了12周，病情已得到控制。该研究旨在评估继续使用该复方制剂治疗9个月（即总共12个月）的疗效和耐受性。每3个月对疾病状况和实验室数据进行评估。在12个月期间症状得到了合理控制，尽管大多数患者没有出现具有临床意义的变化。随着研究的进展，观察到水肿、呼吸困难和端坐呼吸有总体增加的趋势，但考虑到患者的年龄组，这些变化并不被认为异常。脉搏率显著增加，血压下降，表明利尿作用得以维持。该复方制剂耐受性良好，未报告任何副作用。
